GH1 and Noonan syndrome: That same year, the Food and Drug Administration (FDA) approved recombinant human GH for pediatric GHD patients [11,12]. Over time, the therapeutic use of recombinant human GH (rhGH) was approved for additional conditions such as chronic renal insufficiency, adult GHD, Turner syndrome, idiopathic short stature, and Noonan syndrome, among others [12].